  (a) In general
     A manufacturer that is the sole manufacturer of a drug–
    (1) that is–
      (A) life-supporting;
      (B) life-sustaining; or
      (C) intended for use in the prevention of a debilitating disease or condition;
    (2) for which an application has been approved under section 355(b) or 355(j) of this title; and
    (3) that is not a product that was originally derived from human tissue and was replaced by a recombinant product,
       shall notify the Secretary of a discontinuance of the manufacture of the drug at least 6 months prior to the date of the discontinuance.
  (b) Reduction in notification period
     The notification period required under subsection (a) of this section for a manufacturer may be reduced if the manufacturer certifies to the Secretary that good cause exists for the reduction, such as a situation in which–
    (1) a public health problem may result from continuation of the manufacturing for the 6-month period;
    (2) a biomaterials shortage prevents the continuation of the manufacturing for the 6-month period;
    (3) a liability problem may exist for the manufacturer if the manufacturing is continued for the 6-month period;
    (4) continuation of the manufacturing for the 6-month period may cause substantial economic hardship for the manufacturer;
    (5) the manufacturer has filed for bankruptcy under chapter 7 or 11 of title 11; or
    (6) the manufacturer can continue the distribution of the drug involved for 6 months.
  (c) Distribution
     To the maximum extent practicable, the Secretary shall distribute information on the discontinuation of the drugs described in subsection (a) of this section to appropriate physician and patient organizations.
